DNA sequencing pioneer named as BBSRC Innovator of the Year
Prof Shankar Balasubramanian is recognised for the invention of Solexa genome sequencing
Balasubramanian, from the University of Cambridge, is the inventor of Solexa sequencing, an ultrafast method for sequencing DNA. He founded Solexa with colleagues in 1998. Following several rounds of fund raising and the launch of its core product, The Genome Analyser, the company was sold to Illumina for US$600m in 2007. The Solexa product currently has a 50% market share in next generation sequencing and can sequence a human genome for under US$10,000.
Balasubramanian also won the Commercial Innovator of the Year category.
Dr Michael McArthur from the John Innes Centre was awarded £5,000 as the winner of Most Promising Innovator of the Year for his work on using novel antibacterials to combat drug resistant bacterial infections.
Science and Innovation Minister Lord Drayson said: ‘Turning research into innovation is crucial for our future prosperity. Finding practical applications for scientific discoveries is part of the joy of science. Today's winners make science exciting and relevant, with the potential to generate great benefits for our economy and society.’
Balasubramanian accepted the Innovator of the Year Award on behalf of the many people who have made important contributions to the Solexa project, particularly his departmental colleague, Prof David Klenerman, with whom he co-founded Solexa in 1998.
‘None of this would have happened without the support of BBSRC. Their backing was essential for the blue skies research that gave rise to our original inventions. The continued funding of fundamental science by BBSRC will be an essential part of future enterprises and ultimately, wealth creation,’ he said.
The Innovator of the Year Award, now in its second year, recognises and rewards scientists who are ensuring that the UK's bioscience research is translated into outcomes that positively affect quality of life for everyone.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
UK clinical trial reforms come into force in largest regulatory overhaul in 20 years
The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Research & Development
Epitopea receives MHRA approval for first-in-human trial of RNA vaccine for ovarian cancer
The company has received regulatory approval from the MHRA and Regional Ethics Committee to initiate its OVACT Phase I/Ib clinical trial of CryptiVax-1001, an off-the-shelf mRNA immunotherapy targeting high-grade serous ovarian cancer
Research & Development
NEUVIOR Pharmaceuticals receives Innovate UK grant to explore bio-based materials for circular pharmaceutical manufacturing
The Innovate UK feasibility grant will advance its ZYLON programme, which involves clean-chemistry lab trials exploring how bio-derived materials could replace harder-to-recycle packaging formats and reduce waste in pharmaceutical manufacturing
Research & Development
Awen Oncology secures seven-figure funding to advance rare bone cancer therapeutic programme
The cancer therapeutics company has secured seven-figure funding led by biotech investor Dr Urs Spitz to progress its lead programme targeting a rare form of bone cancer with potential broader oncology applications towards clinical development
Research & Development
Leinco Technologies and CellCarta partner to advance proteomics solutions for discovery and drug development
The pair have announced a strategic collaboration combining Leinco's IHC and spatial biology-validated antibody portfolio with CellCarta's CPTAC-validated Immuno-MRM assay resources to enhance proteomic analysis for immuno-oncology and targeted therapy development
Research & Development
Biognosys collaborates with Michael J. Fox Foundation to develop biomarker assays for Parkinson's research
The pair will work to develop highly sensitive, quantitative biomarker assays targeting LRRK2, the most common genetic risk factor for late-onset Parkinson's disease, in support of the foundation's global LITE initiative spanning more than 50 academic, industry and clinical partners